Shimizu H, Ohtani K, Tanaka Y, Fukatsu A, Uehara Y, Sato N, Mori M
First Department of Internal Medicine, Gunma University School of Medicine, Japan.
Thromb Haemost. 1995 Nov;74(5):1231-4.
Hypercoagulability may increase the risk of cardiovascular disease (CVD) in diabetic patients with albuminuria. Plasma thrombin-anti-thrombin III complex (TAT) levels, representing a functional state of clotting system, were studied in one hundred and fifteen non-insulin-dependent diabetic (NIDDM) patients. The patients were divided into three groups according to the urine albumin index (UAI: mg/g Cr): Group A; UAI < 30, Group B; 30 < UAI < 300, Group C; UAI > 300. The effect of albuminuria on plasma TAT levels was significant (p < 0.02). Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks significantly (p < 0.0005) decreased plasma TAT levels. These data indicate that the degree of diabetic albuminuria is related to plasma TAT levels in NIDDM patients and that treatment with EPA may reduce TAT levels and possibly therefore the rate of development of CVD in patients with NIDDM.
高凝状态可能会增加糖尿病合并蛋白尿患者患心血管疾病（CVD）的风险。对115例非胰岛素依赖型糖尿病（NIDDM）患者的血浆凝血酶 - 抗凝血酶III复合物（TAT）水平进行了研究，该水平代表凝血系统的功能状态。根据尿白蛋白指数（UAI：mg/g Cr）将患者分为三组：A组，UAI < 30；B组，30 < UAI < 300；C组，UAI > 300。蛋白尿对血浆TAT水平的影响显著（p < 0.02）。二十碳五烯酸乙酯（EPA：1800 mg/天）治疗4周后，血浆TAT水平显著降低（p < 0.0005）。这些数据表明，NIDDM患者的糖尿病蛋白尿程度与血浆TAT水平相关，EPA治疗可能会降低TAT水平，从而可能降低NIDDM患者CVD的发生率。
